Form 4: Rocket Pharmaceuticals Director Receives Restricted Stock Units as Consulting Compensation

Mikael Dolsten, a director at Rocket Pharmaceuticals, received 14,220 restricted stock units (RSUs) as part of a consulting agreement.

Summary

• Mikael Dolsten, a director of Rocket Pharmaceuticals, Inc., received 14,220 restricted stock units (RSUs) on March 5, 2025.
• These RSUs were granted as compensation for services related to the company's research and development activities, under a consulting agreement effective March 3, 2025.
• The RSUs are valued at $125,000, based on the closing price of Rocket Pharmaceuticals' common stock on March 3, 2025.
• The RSUs will vest on December 31, 2025, and convert to common stock on a one-for-one basis.
• Following the transaction, Dolsten beneficially owns 14,220 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of RSUs to a director suggests continued engagement and alignment of interests, which is generally viewed favorably. There are no explicit negative indicators.

Positives

• The consulting agreement suggests continued engagement of Mikael Dolsten in Rocket Pharmaceuticals' research and development activities.
• The grant of RSUs aligns Dolsten's interests with the company's long-term performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting date of the RSUs.

Industry Context

The granting of stock-based compensation to consultants and directors is a common practice in the biotechnology industry to align their interests with the company's success and conserve cash.

Related Party Transactions

• The consulting agreement between Rocket Pharmaceuticals and director Mikael Dolsten constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign of aligning director interests with company performance.
• Employees may see this as a sign of continued investment in research and development.

Key Dates

Keywords

Rocket Pharmaceuticals, RSU, Restricted Stock Units, Director, Mikael Dolsten, Compensation, Consulting Agreement, Research and Development, Form 4, Beneficial Ownership